Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: JF Quinnelly who wrote (781)	9/1/1998 1:40:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 1728

Affymetrix Issued U.S. Patent Covering Gene Expression Monitoring Preliminary Injunction Motion Filed Against Incyte/Synteni biz.yahoo.com Because of the unique facts surrounding the issuance of the '992 Patent, Affymetrix took the unusual step of filing a motion for a preliminary injunction to ask the Court to immediately stop Incyte/Synteni from making, using and selling products that use Affymetrix' technology. Affymetrix filed for a preliminary injunction after discovering that the claims of the '992 Patent had previously been sought by Synteni inventors. The U.S. Patent Office awarded this key patent to Affymetrix instead of Synteni after recognizing that Affymetrix filed for patent protection more than 4 years earlier than Synteni. ''This patent provides key technology used with spotted arrays for genetic analyses such as expression monitoring,'' said Dr. Stephen P.A. Fodor, President and Chief Executive Officer of Affymetrix. ''In light of the licensing program we have initiated, and the licenses we have already signed to allow others to have freedom to operate in the spotted DNA array field, it is unfortunate that Incyte has chosen to ignore Affymetrix' rights.''